Boston Scientific Unit Launches Multi-Tranche Euro Notes to Fund $14.5B Penumbra Deal
BSX is trading near its 52-week low of $39.57 (10.0% above the low).
Summary
Boston Scientific's Dutch finance arm is marketing six series of guaranteed euro notes to help fund the ~$14.5 billion Penumbra acquisition, with a 101% special mandatory redemption if the deal fails to close by the Outside Date.
Key Events · Financing and Capital Events · BSX
-
Six-Series Euro Notes Offered
American Medical Systems Europe B.V. is offering one floating-rate series (three-month EURIBOR plus a spread) and five fixed-rate series, all fully and unconditionally guaranteed by Boston Scientific on a senior unsecured basis. Amounts, coupons and maturities are left blank in this preliminary prospectus supplement.
-
Proceeds Fund Penumbra Acquisition
Net proceeds, together with a concurrent USD notes offering, short-term borrowings and cash, finance the cash consideration for the Penumbra deal valued at $374 per share, or approximately $14.5 billion, when announced on January 14, 2026.
-
101% Special Mandatory Redemption
If the acquisition is not completed by the Outside Date (January 14, 2027, extendable to no later than January 14, 2028) or Boston Scientific abandons the deal, the fixed-rate notes must be redeemed at 101% of principal plus accrued interest. Proceeds are not escrowed and no lien secures that redemption.
-
Leverage Rises on Top of $11.95B
Boston Scientific had approximately $11,952 million of unsecured indebtedness and no secured debt at September 30, 2026; AMS Europe had approximately $6,217 million. The new notes rank equally with that debt and structurally junior to subsidiary obligations.
Analysis · BSX · Industrial Applications And Services
Boston Scientific's Dutch finance subsidiary is selling six series of euro notes — one floating-rate and five fixed-rate — with the parent guaranteeing them fully and unconditionally. The cash goes toward the ~$14.5 billion Penumbra acquisition announced January 14, 2026 and approved by Penumbra shareholders on May 6, 2026, alongside a separate dollar-denominated notes offering being run at the same time. Bondholders get a key protection in the form of a special mandatory redemption: if the deal does not close by the Outside Date (January 14, 2027, extendable to no later than January 14, 2028) or Boston Scientific walks away, the fixed-rate notes are redeemed at 101% of principal. That backstop is weaker than it looks, because the proceeds are not escrowed and no lien secures the redemption. For equity holders this is debt-funded M&A rather than share issuance, so there is no dilution — but it adds leverage on top of roughly $11.95 billion of unsecured debt already outstanding at September 30, 2026, and comes while the company is still absorbing the August 25 cyberattack that forced it to cut 2026 guidance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSX was trading at $43.51 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $63.3B. The 52-week trading range was $39.57 to $101.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.